CAR-T (chimeric antigen receptor T-cell therapy) genetically engineers a patient's own T cells to recognize and attack cancer cells — in essence, a 'living drug'.
1. Mature in blood cancers: CAR-T is already an important option for relapsed/refractory leukemia, lymphoma and multiple myeloma.
2. Why solid tumors are hard: no ideal single target, immunosuppressive tumor microenvironment, poor cell infiltration — solid-tumor CAR-T struggled for a decade.
3. Significance of Shuriciolen-C: in June 2026, the world's first solid-tumor CAR-T was approved in China; Jiahui International Hospital became one of the first institutions to offer it clinically and completed the world's first international solid-tumor CAR-T patient.
4. How international patients benefit: based on an approved drug, overseas patients can access treatment through standardized clinical channels without waiting for clinical trial slots. Recommended path: submit complete medical records and imaging → multidisciplinary indication assessment at the hospital → leukapheresis and cell manufacturing if eligible → travel to Shanghai for infusion and follow-up. MedBridge Shanghai provides medical record pre-screening, hospital liaison, twelve-language accompaniment, and visa and itinerary coordination — keeping the entire pathway standardized and transparent.
How MedBridge Shanghai Helps
As a leading cross-border medical platform in Shanghai, MedBridge Shanghai provides end-to-end support: free medical record review and specialist appointments, pre-travel coordination and visa support, airport pickup and accommodation, full medical interpretation and coordination, and post-treatment follow-up with remote consultations.
For more information on CAR-T treatment options and costs, contact our medical advisors, or explore our medical services and partner hospitals.
[Disclaimer] This article is not medical advice. Indications, costs and availability of cell therapy must be confirmed by in-person physician evaluation and the hospital's official plan.